Figure 2From: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignanciesProgression-free survival. Symbols on the plot indicate censored patients. Analysis excludes the second retreatment for 3 systemic anaplastic large cell lymphoma patients.Back to article page